PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22713701-4	2012	Multivariate analyses revealed that patients who were heterozygous as well as those who were homozygous for the UGT1A4*3 allelic variant had significantly higher concentrations of the major metabolite olanzapine 10-N-glucuronide in serum (+38% (P = 0.011) and +246% (P < 0.001), respectively).	Olanzapine 10-N-glucuronide	201-228	UDP glucuronosyltransferase family 1 member A4	Homo sapiens	112-118	
21750471-6	2011	The UGT1A4 variant exhibited a 3.7-fold (P<0.0001) higher Vmax/KM for the formation of the olanzapine-10-N-glucuronide isomer 1, and a 4.3-fold (P<0.0001) higher Vmax/KM for the formation of the olanzapine-10-N-glucuronide isomer 2 than wild-type UGT1A4.	Olanzapine 10-N-glucuronide	94-121	UDP glucuronosyltransferase family 1 member A4	Homo sapiens	4-10	
21750471-6	2011	The UGT1A4 variant exhibited a 3.7-fold (P<0.0001) higher Vmax/KM for the formation of the olanzapine-10-N-glucuronide isomer 1, and a 4.3-fold (P<0.0001) higher Vmax/KM for the formation of the olanzapine-10-N-glucuronide isomer 2 than wild-type UGT1A4.	Olanzapine 10-N-glucuronide	201-228	UDP glucuronosyltransferase family 1 member A4	Homo sapiens	4-10	
21750471-10	2011	In regression analysis, the UGT1A4*3 (P<0.02) and UGT2B10*2 (P<0.002) alleles were significant predictors of the formation of all olanzapine glucuronide isomers.	Olanzapine 10-N-glucuronide	136-158	UDP glucuronosyltransferase family 1 member A4	Homo sapiens	28-34